TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Today

Rule Breakers article.

TMFBiologyFool published an update. 3 hours ago

Rule Breakers article.

TMFBiologyFool published an update. 4 hours ago

NL

Article

TMFBiologyFool published an article 4 hours ago

Orkambi a 2016 Blockbuster? Vertex Pharmaceuticals Incorporated Thinks So

Management sees Orkambi sales on track for $1 billion this year.

NL

Article

TMFBiologyFool published an article 4 hours ago

Celgene Corporation Short-Term, Long-Term Guidance Up. Medium-Term? Not So Much

Fortunately the adjustment to medium-term 2017 guidance was widely expected.

NL

Article

TMFBiologyFool published an article 11:52 AM

Why St. Jude Medical, Inc. Acquired a Higher Price Today

Abbott agrees to buy the medical-device maker.

Yesterday

NL

Article

TMFBiologyFool published an article 3:00 PM

Baxter International Inc's Cost-Cutting Paying Off

Sales of the company's healthcare products are stagnant, but earnings see a nice bump higher.

Rule Breakers article.

TMFBiologyFool published an update. 1:24 PM

NL

Article

TMFBiologyFool published an article 12:37 PM

3 Things to Watch as Celgene Corporation Reports Earnings

Revlimid will drive the revenue number, but look to the future.

Tue Apr 26

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 5:17 PM

NL

Article

TMFBiologyFool published an article 1:25 PM

Exelixis, Inc.'s Cabometyx Approved: Let the Kidney Cancer Battle Begin!

Former partners are set to battle it out in the marketplace.

Sun Apr 24

Rule Breakers article.

TMFBiologyFool published an update. 11:57 PM

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 9:03 PM

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 7:16 PM

Supernova Boards Post

TMFBiologyFool replied to the Supernova boards. 6:34 PM

Fri Apr 22

NL

Article

TMFBiologyFool published an article 4:11 PM

Biogen Inc Earnings Explode Higher, Revenue Not So Much

Revenue at biotech isn't increasing as fast though.

Supernova Boards Post

TMFBiologyFool replied to the Supernova boards. 3:49 PM

Thu Apr 21

Supernova Boards Post

TMFBiologyFool replied to the Supernova boards. 12:04 PM

Wed Apr 20

Supernova Boards Post

TMFBiologyFool posted to the Supernova boards. 6:42 PM

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 5:53 PM

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 4:43 PM

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 92.54
Player Rank 5584 out of 74845
Score 921.51
Score Change Today +40.64
Accuracy 67.14%
Active Picks 73
Total Picks 215
Best Pick MNKD (+235.52)
Worst Pick INCY (-644.51)
Average Score per Pick 4.29
Charms Earned 10
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Big red star, 1000 posts CAPS All Star SN Explorer 1 Mission Team Member SN Odyssey
Board Posts 1198
Recs Received 1619
People who have rec'd these posts 550
Recs to Posts Ratio (last 30 days) 6.40
Threads Started 130
Threads Started Percentage 10.85 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 53.92 %
Show TMFBiologyFool’s 10 Latest Posts